Guardant Health enters its third-quarter report with an unusual problem for a cancer diagnostics company: almost everything it was waiting for has already happened. FDA approval of its Guardant360 Liquid companion diagnostic, inclusion of the SHIELD blood test in American Cancer Society colorectal screening guidelines, and a coverage decision from UnitedHealth all arrived around the last report. Now investors need proof that those catalysts are showing up as tests, revenue and better unit economics, rather than simply as a stronger story.

Wall Street expects a non-GAAP loss of $0.29 per share on revenue of about $350.8 million, which would be roughly 32% growth from $265.2 million a year ago. The Earnings Whisper sits at a loss of $0.28, a hair better than consensus, suggesting a slightly higher bar but not a dramatically different one. The more telling comparison is with guidance. Management lifted its 2026 revenue outlook to $1.34 billion to $1.36 billion from $1.30 billion to $1.32 billion, yet the full-year consensus of $1.31 billion still sits below the bottom of that range. With $637 million booked in the first half, the company needs roughly $703 million to $723 million in the back half. A third quarter near $351 million would leave little cushion for the low end, and the implied sequential gain of about $16 million is modest next to the $33 million step-up from the first quarter to the second. In short, the Street looks conservative relative to management, which leaves room for upside if the momentum described last quarter is real.

SHIELD is the center of that question. The test delivered $53 million and 66,000 tests last quarter, up from 44,000 in the first quarter, and management raised its full-year volume target to 270,000 to 285,000 tests. That math requires an average of roughly 80,000 to 88,000 tests in each of the final two quarters, so a third-quarter figure comfortably above 70,000 would validate the raise, while something flat with the second quarter would challenge it. UnitedHealth coverage took effect August 1, giving this report two months of contribution, and the state mandates tied to guideline inclusion should begin to help as well. Price is the trade-off. SHIELD's average selling price of about $800 is expected to face dilution from commercial mix, and the UnitedHealth pricing benefit may take a year or more to show up. Investors should look for evidence that volume is outrunning that dilution, and for early signs that the newly approved lower-cost workflow is moving cost per test down from roughly $410.

The oncology business needs to stay hot. Oncology volume grew 63% last quarter, and Reveal has more than doubled for three straight quarters. Holding gross margin around 67% while absorbing a fast-growing, still-unprofitable screening product would show the cost savings from the sequencing platform transition are sticking. Biopharma and data, which slowed to 9% growth, remains the soft spot; another deceleration would not break the thesis but would draw questions. Cash burn also deserves attention, since the free cash flow outlook was widened to $195 million to $205 million to fund SHIELD lab capacity.

Sentiment has cooled noticeably, moving from mildly bullish before the last report to moderately bearish now, even as the stock rose about 9.6% since then, outpacing the S&P 500 by roughly six points. At around $178, shares sit well above the 200-day average near $129 but about 7% below the post-earnings high of $191, in the middle of a range far tighter than last quarter's wild swing from $89 to $174. That mix of gains and skepticism suggests investors believe the story but are wary of paying up further without confirmation.

The verdict will hinge on whether SHIELD volume accelerates enough to make management's raised targets look achievable, not aspirational. If it does, the gap between consensus and guidance gives Guardant room to beat and potentially raise again. If it stalls, the past quarter's catalysts will look more like headlines than inflection points.